Overview
DSGN market data
Price History
DSGN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for DSGN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1Benzinga · Jun 30, 2026, 12:10 PM
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On WednesdayBenzinga · May 20, 2026, 2:05 PM
Design Therapeutics Stock Wobbles After Rare Genetic Disease DataBenzinga · May 18, 2026, 6:30 PM
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In MayBenzinga · May 18, 2026, 6:30 PM
Nasdaq Down 200 Points; Brady Earnings Top ViewsBenzinga · May 18, 2026, 4:25 PM
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich AtaxiaGlobenewswire Inc · May 18, 2026, 11:15 AM
8-K filing — Design Therapeutics, Inc. (DSGN)SEC EDGAR · May 18, 2026, 11:15 AM
Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability ScoreBenzinga · May 18, 2026, 11:10 AM
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care StockBenzinga · May 15, 2026, 11:50 AM
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga · May 11, 2026, 12:02 PM